Sanna Marco, Caocci Giovanni, La Nasa Giorgio
Hematology Unit, Department of Medical Sciences and Public Health, Bone Marrow Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy.
Mediterr J Hematol Infect Dis. 2017 Aug 14;9(1):e2017047. doi: 10.4084/MJHID.2017.047. eCollection 2017.
Glucose-6-phosphate dehydrogenase (G6PD) represents a common human enzyme defect, particularly prevalent in the Mediterranean, African e Asian area, where malaria was or is still endemic. Recently, we identified G6PD deficiency as a risk factor for developing invasive fungal disease (IFD) and particularly Candida Sepsis in patients undergoing intensive chemotherapy for acute myeloid leukemia (AML), suggesting that there is an urgent need for strategies to properly manage this kind of patients at high risk of invasive mycoses. Here we propose our algorithm for correct identification, prophylaxis, and treatment of IFD in patients with G6PD deficiency undergoing intensive chemotherapy for AML.
